Targeting Adenosine A2A Receptors in Parkinson's Disease

靶向腺苷 A2A 受体治疗帕金森病

• 批准号: 7113900
• 负责人: MICHAEL A SCHWARZSCHILD
• 金额: $ 1万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-03 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7113900
• 关键词: Parkinson' s disease; meeting /conference /symposium; neuropharmacology; purinergic receptor; travel

DESCRIPTION (provided by applicant): Recent insights into the CMS functions of the adenosine A2A receptor, its remarkable anatomical specificity for the basal ganglia, refinements in A2A receptor pharmacology and intriguing environmental clues have all converged to markedly enhance the potential of A2A antagonists as a novel therapeutic strategy for Parkinson's disease (PD). To achieve the proposal's major goal of facilitating the translation of advances in A2A receptor biology into well-designed clinical trials for PD, we propose holding an authoritative international conference that systematically covers the promise of A2A antagonists for PD - from basic science to preclinical and clinical studies. The conference, entitled "Targeting A2A adenosine receptors in Parkinson's disease", is planned for May 17-19 in Boston and will be hosted by Massachusetts General Hospital and its Mass General Institute for Neurodegenerative Disease. The event follows four years after our similarly focused meeting, and is designed to build on the momentum achieved through subsequent basic science and clinical advances. For example, recent laboratory insights into the heteromeric interactions of A2A with D2 dopamine and mGluS glutamate receptors, and clinical trial outcomes demonstrating antiparkinsonian efficacy of an A2A antagonist have created new opportunities for further therapeutic progress for PD and other CMS disorders. The conference sessions are organized over sequential themes: 1) fundamentals of A2A receptor biology, 2) A2A in basal ganglia physiology, 3) basis for the symptomatic motor benefits of A2A antagonists, 4) potential neuroprotective effects of caffeine and more specific A2A antagonists, 5) potential anti-dyskinetic effects of antagonists, 6) A2A receptors in non-motor CMS systems affecting sleep/mood/psychosis/addiction, and 7) translating these insights into effective, safe clinical trials for PD. Presentations from a diverse mix of established and young investigators (supported by a travel fellowship program for minority/underrepresented scientists), together with participation from a range of attendees spanning academia and industry will foster a fruitful exchange of information and ideas. This educational forum will extend well beyond the conference with the publication of its proceedings. Thus this timely conference is designed to catalyze the development of A2A antagonists as a novel multi-faceted treatment strategy for Parkinson's disease and related CMS disorders.

描述（申请人提供）：对腺苷A2A受体的CMS功能的最新见解，其对基底神经节的显着解剖学特异性，A2A受体药理学的改进和吸引人的环境线索都融合了A2A拮抗剂作为新型治疗策略的潜在抗潜在的parkinson疾病（PD -DD）。 为了实现该提案的主要目标，即促进A2A受体生物学的进步转化为PD精心设计的临床试验，我们建议举行一次权威的国际会议，该会议系统地涵盖了PD的A2A拮抗剂的希望 - 从基础科学到抗尖锐和临床研究。 该会议计划于5月17日至19日在波士顿举行，题为“针对帕金森氏病中的A2A腺苷受体”，将由马萨诸塞州综合医院及其大规模神经退行性疾病研究所主持。 这次活动是在我们同样集中的会议之后的四年之后，旨在基于随后的基础科学和临床进步所取得的势头。 例如，最近对A2a与D2多巴胺和谷氨酸受体的异源相互作用的实验室见解，以及临床试验结果，证明了A2A拮抗剂的反帕金森氏症功效，为PD和其他CMS疾病的进一步治疗进展创造了新的机会。 The conference sessions are organized over sequential themes: 1) fundamentals of A2A receptor biology, 2) A2A in basal ganglia physiology, 3) basis for the symptomatic motor benefits of A2A antagonists, 4) potential neuroprotective effects of caffeine and more specific A2A antagonists, 5) potential anti-dyskinetic effects of antagonists, 6) A2A receptors in non-motor CMS systems affecting睡眠/情绪/精神病/成瘾，以及7）将这些见解转化为PD有效，安全的临床试验。 来自各种成熟和年轻研究人员的演讲（在少数民族/代表性不足的科学家的旅行奖学金计划的支持下），以及来自学术界和行业的各种参与者的参与将促进信息和思想的富有成效的交流。 随着诉讼的发布，这个教育论坛将远远超出会议。 因此，这次及时的会议旨在促进A2A拮抗剂的发展，作为帕金森氏病和相关CMS疾病的新型多面治疗策略。